Registered Charity No: 1156027 (England & Wales).
What do we do?:
Increase survival rates, reduce morbidity and improve quality of life for men with prostate cancer
Provide a better future for men and their families affected by prostate cancer
Our focus is on taking research from bench to bedside. To achieve this key goal, we:
- Help our researchers connect with patients so that they have a deeper understanding of patients’ needs and challenges
- Assist our scientists in building new collaborations and partnerships with other scientists
- Monitor and evaluate our impact to ensure the effectiveness of our research and continue to improve our work in the future
Only by working in this way do we have a good chance of saving and improving lives.
Prostate cancer is 2nd most common cause of cancer death in men and by 2030 it is predicted to be the most common cancer in the UK.
In the UK, more than 56,000 men were diagnosed with prostate cancer in 2018, 5,000 of whom were under the age of 60. Of those men diagnosed in the UK, more than 12,000 die from the disease each year. Because of increased life expectancy, the number of deaths from prostate cancer is predicted to rise by as much as 8% per year.
With over 30 years of experience, we fund high-quality medical research projects at some of the UK’s leading institutions in prostate cancer, ranging from early-stage research to drug development. In 2019 we increased our number of grants by 175%, and so while our mission remains unchanged, we have embarked on a bold new chapter. We are not only scaling up our research capacity, but changing our approach by connecting our scientists and patients, and diversifying our funding portfolio. Our sights are set high for the future and we won’t rest until we find better treatments for prostate cancer.
Why are legacies important to us?:
Your Will is a way to ensure that once those close to you are looked after, you can continue to support a cause you care about. We urgently need to develop new and effective treatments for men with advanced prostate cancer to save lives and support families. It is in the late stages of the disease that prostate cancer kills yet but doctors are often restricted to using treatments for late-stage prostate cancer that are toxic and prolong life by only a few months.
Globally, the funding of medical research into improved treatments for prostate cancer remains minimal. In the UK, according to the National Cancer Research Institute, just over £22m was spent overall on novel prostate cancer research in 2018. By way of comparison, £40–£46m has been spent on early-stage breast cancer research over the last five years, and with this considerable investment mortality rates for breast cancer have fallen by 18% since 2014.
This is where the Prostate Cancer Research (PCR) comes in to the picture – we are here to invest in the essential science, research and medical breakthroughs of the future.
PCR is extremely grateful for any gift left via a Will. Legacies play a major part in our ability to invest in essential scientific research.